BD’s Advanced Bioprocessing business acquired by Thermo Fisher Scientific

Becton, Dickinson and Company’s Advanced Bioprocessing business unites a strong technical services program with peptones that improve cell culture media formulations to increase yield and decrease variability in biopharmaceutical applications, with annual revenue at around $100 million. BD have agreed to the acquisition of this part of their business by Thermo Fisher Scientific who will integrate it into their Life Sciences Solutions Segment.
Thermo Fisher Scientific’s EVP and COO, Mark Stevenson, said: “Thermo Fisher has a trusted value proposition for customers who are working in biologic drug development and manufacturing. The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production.”
BD’s president of Life Sciences, Patrick Kaltenbach, said: “We are excited that our Advanced Bioprocessing team will have the opportunity to join a company with deep expertise and a long-standing commitment to supporting biopharmaceutical production. It will create new prospects, building on a 25-year history of ensuring that high-quality biopharmaceuticals get to the market quickly.”